All In Biotech

Drug Trial Radar · NCT01954394

Open Label Study of Long Term Safety Evaluation of Alirocumab

Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

986

Actual

Start

Dec 17, 2013

Primary completion

Jun 30, 2017

Study completion Jun 30, 2017

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Oct 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831). Secondary Objectives: * To evaluate the long-term efficacy of alirocumab on lipid parameters. * To evaluate the long-term immunogenicity of alirocumab.

Conditions

  • Hypercholesterolemia

Interventions

  • AlirocumabDrug

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

  • Lipid-Modifying Therapy (LMT)Drug

    Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced Adverse Events (AEs)Time frame: Up to 10 weeks after last study drug administration (maximum of 176 weeks)

Locations

177 sites in 24 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840321

    Huntsville, Alabama

  • Investigational Site Number 840341

    Tempe, Arizona

  • Investigational Site Number 840334

    Bell Gardens, California

  • Investigational Site Number 840319

    Fountain Valley, California

  • Investigational Site Number 840336

    Los Angeles, California

  • Investigational Site Number 840339

    Mission Viejo, California

  • Investigational Site Number 840337

    Newport Beach, California

  • Investigational Site Number 840306

    Golden, Colorado

  • Investigational Site Number 840328

    Washington D.C., District of Columbia

  • Investigational Site Number 840344

    Atlantis, Florida

  • Investigational Site Number 840353

    Clearwater, Florida

  • Investigational Site Number 840318

    Fort Lauderdale, Florida

  • Investigational Site Number 840327

    Jacksonville, Florida

  • Investigational Site Number 840309

    Miami, Florida

  • Investigational Site Number 840351

    Sarasota, Florida

  • Investigational Site Number 840315

    Evanston, Illinois

  • Investigational Site Number 840305

    Oakbrook Terrace, Illinois

  • Investigational Site Number 840333

    Iowa City, Iowa

  • Investigational Site Number 840329

    Kansas City, Kansas

  • Investigational Site Number 840345

    Auburn, Maine

  • Investigational Site Number 840338

    Biddeford, Maine

  • Investigational Site Number 840322

    Boston, Massachusetts

  • Investigational Site Number 840346

    Framingham, Massachusetts

  • Investigational Site Number 840317

    St Louis, Missouri

  • Investigational Site Number 840349

    St Louis, Missouri

  • Investigational Site Number 840314

    Morristown, New Jersey

  • Investigational Site Number 840316

    New York, New York

  • Investigational Site Number 840324

    Poughkeepsie, New York

  • Investigational Site Number 840303

    Charlotte, North Carolina

  • Investigational Site Number 840320

    Durham, North Carolina

  • Investigational Site Number 840348

    Raleigh, North Carolina

  • Investigational Site Number 840340

    Cincinnati, Ohio

  • Investigational Site Number 840302

    Marion, Ohio

  • Investigational Site Number 840330

    Portland, Oregon

  • Investigational Site Number 840352

    Beaver, Pennsylvania

  • Investigational Site Number 840308

    Philadelphia, Pennsylvania

  • Investigational Site Number 840342

    Scranton, Pennsylvania

  • Investigational Site Number 840304

    Summerville, South Carolina

  • Investigational Site Number 840311

    Dallas, Texas

  • Investigational Site Number 840312

    Dallas, Texas

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.